Patent ID: 6369101
Filing Date: 2002-04-09
Classification: A61K,C07D

Abstract:
A therapeutic method for treating a human afflicted with herpesvirus infection comprising administering to said human, an effective anti-viral amount of a compound of formula whereinone of R1 and R2 is â€”Oâ€”Y and the other is hydrogen or (C1-C6)alkyl optionally substituted by hydroxy, (C1-C6)alkoxy, halo, halo(C1-C6)alkoxy or NRjRk wherein Rj and Rk are independently H, (C1-C6)alkyl or (C1-C6)alkonyl; or R1 and R2 together are oxo (&boxH;O); R3 is hydrogen, halo, carboxy, mercapto, (C1-C6)alkyl, (C3-C8)cycloalkyl, or â€”Oâ€”Y; R4 and R5 are each independently hydrogen, (C1-C6)alkyl, or hydroxy(C1-C6)alkyl; R6 is hydrogen or is absent when the adjacentâ€”is a bond; R7 is hydrogen or (C1-C6)alkyl; R8 is hydrogen, (C1-C6)alkyl, or hydroxy(C1-C6)alkyl and R11 is hydrogen, (C1-C6)alkyl, carboxy, or hydroxy(C1-C6)alkyl; or R8 and R11 together are â€”Oâ€”C(&boxH;X)â€”; R9 and R10, are each independently hydrogen or (C1-C6)alkyl; each of the bonds represented by --- is independently absent or is present; X is two hydrogens, oxo (&boxH;O) or thioxo (&boxH;S); each Y is independently H, aryl, P(O)(Cl)2, (C3-C8)cycloalkyl, adamantyl, â€”SO2Ra O&boxH;P(Rb)2, O&boxH;P(Rc)2OP(O)(Rd)â€”, Si(Re)3, tetrahydropyran-2-yl, an amino acid, a peptide, a glycoside, or a 1 to 10 membered branched or unbranched carbon chain optionally comprising 1, 2, or 3 heteroatoms selected from non-peroxide oxy, thio, and â€”N(Rf)â€”; wherein said chain may optionally be substituted on carbon with 1, 2, 3, or 4 oxo (&boxH;O), hydroxy, carboxy, halo, mercapto, nitro, â€”N(Rg)(Rh), (C3-C8)cycloalkyl, (C3-C8)cycloalkyloxy, aryl, aryloxy, adamantyl, adamantyloxy, hydroxyamino, trifluoroacetylamino, a glycoside, an amino acid, or a peptide; and wherein said chain may optionally be saturated or unsaturated Ra is (C1-C6)alkyl or aryl; Rb, Rc, and Rd are each independently hydroxy, (C1-C6)alkoxy, hydroxy(C2-C6)alkoxy, adamantyloxy, adamantyl(C1-C6)alkoxy, norbomyloxy, 1,1-di(hydroxymethyl)-2-hydroxyethoxy, carboxy(C1-C6)alkoxy, 2,3-epoxypropyloxy, benzyloxy, (C3-C8)cycloalkyloxy, NRxRy, or aryloxy; Re is H, aryl or (C1-C6)alkyl; Rf is hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, phenyl or benzyl; Rg and Rh are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, hydroxy(C1-C6)alkyl, adamantyl, adamantyl(C1-C6)alkyl, amino(C1-C6)alkyl, aminosulfonyl, (C1-C6)alkanoyl, aryl and benzyl; or Rband Rc together with the nitrogen to which they are attached form a pyrrolidino, piperidino, or morpholino radical; and Rx and Ry are each independently hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, aryl or benzyl; wherein each aryl of Y, Ra-Rd, Rg-Rh, Rx, and Ry may optionally be substituted by 1, 2, or 3 aminosulfonyl, carboxy, NRiRj, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, halo, nitro, cyano, mercapto, carboxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, trifluoromethoxy, (C1-C6)alkanoyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, or (C1-C6)alkanoyloxy; wherein Ri and Rj are each independently hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, phenyl, or benzyl; or a pharmaceutically acceptable salt thereof; provided the compound is not ursolic acid-3-one and 2,3-dibydroxyurs-12-en-28-oil acid.